(−)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana prevents diabetes and dyslipidemia in streptozotocin-induced diabetic mice
Fig 3
Effects of (−)-epicatechin-3-O-β-D-allopyranoside (BB) including two parts.
(A) oral glucose tolerance (OGTT). OGTT test was performed on 12 h fasted ICR mice (n = 5) that were allowed access to 40, 80, and 160 mg/kg BB or an equivalent amount of vehicle (water), which were given orally 30 min before an oral glucose load (1 g/kg body wt). The control group was given glucose, whereas the normal group was not. Blood samples were collected from the retro-orbital sinus of fasted mice at the time of the glucose administration (0) and every 30 min until 120 minutes after glucose administration and the blood glucose level was monitored. (B)~(F): Effects of BB on streptozotocin (STZ)-induced diabetic mice; (B) blood glucose levels, (C) triglycerides levels, (D) total cholesterol levels, (E) adiponectin levels, and (F) leptin levels at week 4 by oral gavage (−)-epicatechin-3-O-β-D-allopyranoside (BB: B1, B2, and B3, 10, 20 and 40 mg/kg body weight), or metformin (Metf; 300 mg/kg body weight), or fenofibrate (Feno; 250 mg/kg body weight) in streptozotocin (STZ)-induced mice. All values are means ± SE (n = 9). # P < 0.05, ## P < 0.01, and ### P < 0.001 compared with the control (CON) group; * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the streptozotocin plus vehicle (distilled water) (STZ) group by ANOVA.